VivoSeq
Other

Esotropia

3

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Esotropia is an early-stage landscape with 3 programs across 2 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Falcon. 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 3F

Falcon

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Unknown status1 · 100%

Clinical Trials

Trial Activity

Cycloplegic Refraction in Pediatric Patients With Esotropia
Unknown status·—·Phase 4·NCT06077682·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)